BACKGROUND: Intravenous prostacyclin treatment is a well recognized option in patients suffering from pulmonary arterial hypertension (PAH), and remains the gold standard of treatment. However, intravenous prostacyclin treatment involves several limitations, because the available battery-driven pump systems carry the risk of line infections, catheter-related embolisms, thrombosis, and delivery system malfunctions. CASE REPORT: We report for the first time, to the best of our knowledge, on the safe transition procedure from subcutaneous to intravenous treprostinil in a 74-year-old woman suffering from severe PAH (New York Heart Association functional class III), using a new implantable, gas-driven, intravenous pump device (LenusPro, Tricumed/OMT, Frittlingen, Germany). CONCLUSIONS: This implantable pump system may overcome the well-known limitations and risks of commonly used delivery systems, and thus may provide a new option for continuous intravenous prostacyclin treatment in patients with PAH.
BACKGROUND: Intravenous prostacyclin treatment is a well recognized option in patients suffering from pulmonary arterial hypertension (PAH), and remains the gold standard of treatment. However, intravenous prostacyclin treatment involves several limitations, because the available battery-driven pump systems carry the risk of line infections, catheter-related embolisms, thrombosis, and delivery system malfunctions. CASE REPORT: We report for the first time, to the best of our knowledge, on the safe transition procedure from subcutaneous to intravenous treprostinil in a 74-year-old woman suffering from severe PAH (New York Heart Association functional class III), using a new implantable, gas-driven, intravenous pump device (LenusPro, Tricumed/OMT, Frittlingen, Germany). CONCLUSIONS: This implantable pump system may overcome the well-known limitations and risks of commonly used delivery systems, and thus may provide a new option for continuous intravenous prostacyclin treatment in patients with PAH.
Authors: Ralf Ewert; Manuel J Richter; Regina Steringer-Mascherbauer; Ekkehard Grünig; Tobias J Lange; Christian F Opitz; Christian Warnke; Hossein-Ardeschir Ghofrani Journal: Clin Res Cardiol Date: 2017-04-20 Impact factor: 5.460
Authors: Manuel J Richter; Ralf Ewert; Christian Warnke; Henning Gall; Simon Classen; Friedrich Grimminger; Eckhard Mayer; Werner Seeger; Hossein-Ardeschir Ghofrani Journal: Clin Res Cardiol Date: 2016-09-26 Impact factor: 5.460
Authors: Wolfgang Hohenforst-Schmidt; Juergen Hornig; Norbert Friedel; Paul Zarogoulidis; Konstantinos Zarogoulidis; Johannes Brachmann Journal: Drug Des Devel Ther Date: 2013-03-21 Impact factor: 4.162
Authors: Marcin Kurzyna; Katarzyna Małaczyńska-Rajpold; Andrzej Koteja; Agnieszka Pawlak; Łukasz Chrzanowski; Michał Furdal; Zbigniew Gąsior; Wojciech Jacheć; Bożena Sobkowicz; Justyna Norwa; Tatiana Mularek-Kubzdela; Adam Torbicki Journal: BMC Pulm Med Date: 2017-12-02 Impact factor: 3.317